Bickford Pharmaceuticals

Bickford Pharmaceuticals is an early-stage veterinary biotech company focused on regenerative medicine for avian species. The company is developing AviCell, a proposed autologous stem cell-based therapy intended to treat bone and cartilage injuries in birds using bone marrow-derived mesenchymal stem cells. Its website states that the company is seeking FDA drug approval for this proposed avian autologous drug product and is in the beginning stages of growth and development. Bickford Pharmaceuticals appears to be a private company based in New Hampshire and is led by owner and president Erek Bickford. The company positions its technology around efficient treatment of fractures and related injuries in birds.